LeMaitre Q1 2018 Sales $26.0mm (+8%), EPS $0.19 (+17%)

BURLINGTON, Massachusetts, UNITED STATES


BURLINGTON, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2018 results, provided guidance, and announced a $0.07/share dividend.

Q1 2018 Results

  • Sales of $26.0mm, +8% vs. Q1 2017
  • Operating income of $4.9mm vs. $4.2mm, +16%
  • Net income of $3.9mm vs. $3.2mm, +20%
  • Earnings of $0.19 per diluted share vs. $0.16, +17%
  • EBITDA of $5.9mm vs. $5.2mm, +13%

Q1 2018 sales of $26.0mm increased 8% (+3% organic) vs. Q1 2017.  Allografts, patches and valvulotomes led growth.  Sales in the Americas and Europe/Middle East/Africa were up 6% and 15% respectively, while sales in Asia/Pac Rim decreased 11%.

Gross margin decreased to 71.1% in Q1 2018 from 71.9% in Q1 2017, primarily due to product mix and manufacturing inefficiencies.

Operating expenses in Q1 2018 were $13.6mm, a 3% increase vs. the year-earlier quarter. The Company ended the quarter with 94 sales reps vs. 95 at the end of Q1 2017.

George W. LeMaitre, Chairman and CEO said, “We continue to pursue 10% annual reported sales growth and 20% annual operating income growth.”

Business Outlook

 Previous Guidance (2/21/2018)Current Guidance
Q2 2018 SalesN/A$26.6mm - $27.4mm
(Midpoint: +5% reported, +5% organic)
Q2 2018 Gross MarginN/A69.0%
Q2 2018 Operating IncomeN/A$11.1mm - $11.7mm* 
(Midpoint: +106%)
Q2 2018 Earnings Per ShareN/A$0.41 - $0.43
(Midpoint: +83%)
2018 Sales$110.0mm - $111.6mm
(Midpoint: +10% reported, +7% organic)
$106.0mm - $109.0mm
(Midpoint: +7% reported, +6% organic)
2018 Gross Margin71.5%71.0%
2018 Operating Income$25.4mm - $26.6mm
(Midpoint: +23%)
$27.9mm - $30.0mm* 
(Midpoint: +37%)
2018 Earnings Per Share$0.96 - $1.00
(Midpoint: +14%)
$1.05 - $1.13
(Midpoint: +27%)
*Included in operating income guidance is an estimated $5.8mm gain from the divestiture described below.  This amount is subject to change based on final accounting treatment. 

Divestiture of General Surgery Product Lines

On April 5, 2018, the Company divested its general surgery product lines to Symmetry Surgical, Inc. for $7.4 million.  Included in the divestiture were the Reddick Cholangiogram Catheter and Reddick Saye-Screw, both used during laparoscopic cholecystectomy procedures.  With this transaction complete, all of LeMaitre’s remaining 14 product lines are focused on the vascular surgeon.  In 2017, these product lines accounted for $3.3 million in revenue and $2.5 million in gross profit.

Quarterly Dividend

On April 23, 2018, the Company's Board of Directors approved a quarterly dividend of $0.07/share of common stock. The dividend will be paid June 7, 2018 to shareholders of record on May 22, 2018.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today to review the Company's financial results and discuss its business outlook for the remainder of the year. The conference call will be broadcast live over the Internet. Individuals who are interested in listening to the webcast should log on to the Company's website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 844-239-5284 (+1 512-961-6497 for international callers), using passcode 1197775. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc. This press release contains other trademarks and trade names of the Company.

For more information about the Company, please visit http://www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre Vascular management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization. The Company refers to the calculation of non-GAAP sales percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and EBITDA to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, forward-looking statements in this release include, but are not limited to, statements about the Company's expectations regarding Q2 2018 and 2018 sales, gross margin, operating income and earnings per share. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; the risk that assumptions about the market for the Company's products and the productivity of the Company's direct sales force and distributors may not be correct; risks related to the integration of acquisition targets; risks related to product demand and market acceptance of the Company's products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories; and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

      
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)    
CONDENSED CONSOLIDATED BALANCE SHEETS     
(amounts in thousands)    
      
      
   March 31, 2018 December 31, 2017
   (unaudited)  
Assets    
      
Current assets:    
 Cash and cash equivalents $22,781  $19,096 
 Short-term marketable securities  22,613   22,564 
 Accounts receivable, net  14,510   15,000 
 Inventory and other deferred costs  21,833   21,046 
 Prepaid expenses and other current assets  2,271   2,605 
Total current assets  84,008   80,311 
      
Property and equipment, net  12,170   12,378 
Goodwill  23,810   23,844 
Other intangibles, net  7,806   8,234 
Deferred tax assets  1,419   1,378 
Other assets  197   178 
      
Total assets $129,410  $126,323 
      
      
Liabilities and stockholders' equity    
      
Current liabilities:    
 Accounts payable $1,440  $1,543 
 Accrued expenses  9,118   9,770 
 Acquisition-related obligations  2,084   1,876 
Total current liabilities  12,642   13,189 
      
Deferred tax liabilities  2,177   2,176 
Other long-term liabilities  1,121   1,188 
Total liabilities  15,940   16,553 
      
Stockholders' equity    
 Common stock  208   207 
 Additional paid-in capital  94,040   93,127 
 Retained earnings  30,836   28,333 
 Accumulated other comprehensive loss  (2,006)  (2,289)
 Treasury stock  (9,608)  (9,608)
Total stockholders' equity  113,470   109,770 
      
Total liabilities and stockholders' equity $129,410  $126,323 
      


     
 LEMAITRE VASCULAR, INC (NASDAQ: LMAT)  
 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS  
 (amounts in thousands, except per share amounts)   
 (unaudited)   
     
  For the three months ended
  March 31, 2018 March 31, 2017
     
Net sales$25,994 $24,139
Cost of sales 7,520  6,786
     
Gross profit 18,474  17,353
     
Operating expenses:   
 Sales and marketing 7,090  6,954
 General and administrative 4,697  4,548
 Research and development 1,825  1,658
     
     
Total operating expenses 13,612  13,160
     
Income from operations 4,862  4,193
     
Other income:   
 Other income (loss), net 54  46
     
Income before income taxes 4,916  4,239
     
Provision for income taxes 1,063  1,020
     
Net income$3,853 $3,219
     
Earnings per share of common stock   
 Basic$0.20 $0.17
 Diluted$0.19 $0.16
     
Weighted - average shares outstanding:   
 Basic 19,283  18,631
 Diluted 20,181  19,707
     
     
Cash dividends declared per common share$0.070 $0.055
     


         
 LEMAITRE VASCULAR, INC (NASDAQ: LMAT)    
 SELECTED NET SALES INFORMATION      
 (amounts in thousands)       
 (unaudited)       
         
         
  For the three months ended
  March 31, 2018 March 31, 2017
  $ % $ %
Net Sales by Geography       
 Americas$15,860 61% $14,980 62%
 Europe/Middle East/Africa 8,755 34%  7,614 32%
 Asia/Pacific Rim 1,379 5%  1,545 6%
Total Net Sales$25,994 100% $24,139 100%
         


          
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)       
NON-GAAP FINANCIAL MEASURES       
(amounts in thousands)       
(unaudited)       
          
          
Reconciliation between GAAP and Non-GAAP sales growth:       
 For the three months ended March 31, 2018       
  Net sales as reported $25,994      
  Impact of currency exchange rate fluctuations  (1,196)     
  Net impact of acquisitions excluding currency  -      
  Adjusted net sales   $24,798    
          
 For the three months ended March 31, 2017       
  Net sales as reported $24,139      
  Net impact of divestitures excluding currency  -      
  Adjusted net sales   $24,139    
          
  Adjusted net sales increase for the three months ended March 31, 2018 $659  3% 
          
          
Reconciliation between GAAP and Non-GAAP sales growth:       
 For the three months ended June 30, 2018       
  Net sales per guidance $27,025      
  Impact of currency exchange rate fluctuations  (978)     
  Net impact of acquisitions excluding currency  -      
  Adjusted net sales   $26,047    
          
 For the three months ended June 30, 2017       
  Net sales as reported $25,753      
  Net impact of divestitures excluding currency  (852)     
  Adjusted net sales   $24,901    
          
  Adjusted net sales increase for the three months ended June 30, 2018 $1,146  5% 
          
          
Reconciliation between GAAP and Non-GAAP sales growth:       
 For the year ended December 31, 2018       
  Net sales per guidance $107,450      
  Impact of currency exchange rate fluctuations  (2,867)     
  Net impact of acquisitions excluding currency  -      
  Adjusted net sales   $104,583    
          
 For the year ended December 31, 2017       
  Net sales as reported $100,867      
  Net impact of divestitures excluding currency  (2,492)     
  Adjusted net sales   $98,375    
          
  Adjusted net sales increase for the year ended December 31, 2018  $6,208  6% 
          
          
          
    For the three months ended  
    March 31, 2018 March 31, 2017   
Reconciliation between GAAP and Non-GAAP EBITDA       
 Net income as reported $3,853  $3,219    
 Interest (income) expense, net  (95)  (20)   
 Amortization and depreciation expense  1,036   979    
 Provision for income taxes  1,063   1,020    
          
 EBITDA $5,857  $5,198    
          
 EBITDA percentage increase    13%    
          

 


Contact Data